Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s447289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Artur Martynov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory and Clinical department of Molecular Immunopharmacology, SI " I. Mechnikov Institute of Microbiology and Immunology of National Academy of…. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Experimental. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
The paper presents the results of a study on the first synthesized benzimidazole derivatives obtained from labile nature carboxylic acids. The synthesis conditions of these substances were studied, their structure was proved, and some components were found to have sugar-reducing activity on the model of alloxan diabetes in rats.
Methods
The study used molecular modeling methods such as docking based on the evolutionary model (igemdock), RP_HPLC method to monitor the synthesis reaction, and 1H NMR and 13C NMR, and other methods of organic chemistry to confirm the structures of synthesized substances. Results & Discussion: The docking showed that the ursodeoxycholic acid benzimidazole derivatives have high tropics to all imidazoline receptor carriers (PDB ID: 2XCG, 2bk3, 3p0c, 1QH4). The ursodeoxycholic acid benzimidazole derivative and arginine and histidine benzimidazole derivatives showed the highest sugar-lowering activity in the experiment on alloxan-diabetic rats. For these derivatives, the difference in glucose levels of treated rats was significant against untreated control. Therefore, the new derivatives of benzimidazole and labile natural organic acids can be used to create new classes of imidazoline receptor inhibitors for the treatment of diabetes mellitus and hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory and Clinical department of Molecular Immunopharmacology, SI " I. Mechnikov Institute of Microbiology and Immunology of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine.
- R&D Department, Noigel LLC, New York, NY, USA.
- Baylor Scott & White Health, Round Rock, TX, USA.
- SUNY Downstate Medical Center / University Hospital of Brooklyn, New York, NY, USA.
ORCID-Profile: Artur Martynov, Boris Farber, Tatyana Bomko, Daniel L Beckles, Ilya Kleyn
Zitieren
APA
Martynov, A., Farber, B., Bomko, T., Beckles, D. L., & Kleyn, I. (2024). Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s447289
Vancouver
Martynov A, Farber B, Bomko T, Beckles DL, Kleyn I. Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s447289
BibTeX
@article{Martynov2024,
author = {Martynov, Artur and Farber, Boris and Bomko, Tatyana and Beckles, Daniel L and Kleyn, Ilya},
title = {Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s447289}
}
EUVIMED